2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.
IPO Year:
Exchange: NASDAQ
Website: 2seventybio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2024 | $5.00 → $2.00 | Neutral → Sell | Goldman |
| 1/31/2024 | Outperform → Market Perform | TD Cowen | |
| 1/31/2024 | $5.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 10/30/2023 | $6.00 | Outperform → Market Perform | Leerink Partners |
| 10/12/2023 | $13.00 | Buy | Citigroup |
| 9/13/2023 | $5.00 | Buy → Neutral | Goldman |
| 9/12/2023 | Buy → Neutral | Guggenheim | |
| 7/28/2023 | $25.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/31/2022 | $30.00 | Buy | Guggenheim |
| 5/2/2022 | $26.00 | Buy | Goldman |